Volume 1 Issue 1
Research Article: Bioequivalence of two Oral Formulations of Etoricoxib 60 mg Tablets in Healthy Mexican Adults
Araceli G. Medina-Nolasco, Karina L. Ortiz-Campos, Ericka Lopez-Bojorquez, Miguel Angel Arellano-Ibanez, Victoria Burke-Fraga, and Mario Gonzalez-de la Parra*
Etoricoxib is a potent selective Cyclo-oxygenase 2 inhibitor with anti-inflammatory and analgesic properties. Here we investigate the bioavailability and the bioequivalence of a test formulation containing 60 mg of etoricoxib with respect to the corresponding reference drug formulation, which was administered as a tablet. A single-dose randomized, open-label, two-sequence, two-period crossover design under fasting conditions with a 12-day washout interval between the two periods was used.
Samples were drawn at baseline and then at 0.25, 0.5, 0.75, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 12.00, 24.00, 36.00, 48.00 and 72.00 hours after administration.
The 90% CIs for etoricoxib Cmax, and truncated AUC0-72 were 99.55% to 119.33%, and 95.97% to 103.06%, respectively. The 90% CIs of the geometric mean ratios of the two parameters fell within the predetermined range of 80% to 125%. Therefore, these results indicate that the bioequivalence criteria were satisfied.
Cite this Article: Medina-Nolasco AG, Ortiz-Campos KL, Lopez-Bojorquez E, Arellano-Ibanez MA, Gonzalez-de la Parra M, et al. Bioequivalence of Two Oral Formulations of Etoricoxib 60 mg Tablets in Healthy Mexican Adults. Am J Bioavailab Bioequiv. 2018;1(1): 010-014.
Published: 19 May 2018
Research Article: Comparison of Antibacterial Activity of (-) Thioridazine and Racemic Thioridazine in Staphylococcus aureus
Marianne O. Poulsen, Janne K. Klitgaard, Jorn B. Christensen, Birgitte H. Kallipolitis, Glenn W. Kaatz, Per Plenge, Stephen J. Fey and Jette E. Kristiansen*
Antibiotic resistance is an increasing problem globally. Non-antibiotics are therapeutics that have antibacterial properties in addition to their original purposes. Thioridazine is a non-antibiotic that has been shown to sensitize Staphylococcus aureus to classical antibiotics. However, the drug has been withdrawn from the market due to cardiotoxicity. Recent work has shown that the cardiotoxic side-effects are linked to the (+) enantiomer of thioridazine but not to the (-) form. The aim of this work was thus to investigate the antimicrobial efficacy of the (-) enantiomer (-TZ) as compared to the racemic mixture of Thioridazine (TZR). Viability assays on methicillin-sensitive and methicillin-resistant Staphylococcus aureus (S. aureus) strains show that combinations of TZR and-TZ together with Dicloxacillin (DCX) are equally effective showing that selecting the -TZ enantiomer does not compromise its activity. Importantly, -TZ binds with lower affinity to the dopamine 2 receptor, indicating that this formulation might provide therapeutic benefit with reduced side effects. This strengthens the potential for future application of combined treatment using -TZ and classical antibiotics.
Cite this Article: Poulsen MO, Klitgaard JK, Christensen JB, Kallipolitis BH, Kristiansen JE, et al. Comparison of Antibacterial Activity of (-) Thioridazine and Racemic Thioridazine in Staphylococcus aureus. Am J Bioavailab Bioequiv. 2018;1(1): 001-009.
Published: 13 April 2018
Authors submit all Proposals and manuscripts via Electronic Form!
